Advanced Search

 

Study ID Status Title Patient Level Data
712753/007 Completed A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose rosiglitazone/metformin combination therapy compared to both rosiglitazone and metformin monotherapies in drug naive type 2 diabetes mellitus subjects Study Listed on ClinicalStudyDataRequest.com
712753/008 Completed AVANDAMET Compared to Metformin Evaluation Trial (ACME): A 48-week Randomized, Open-label, multicenter study to compare the efficacy and tolerability of AVANDAMET to metformin monotherapy in subjects with Type 2 Diabetes Mellitus who are not achieving glycemic control on submaximal metformin.
712753/009 Completed A 24 week, randomised, double blind, parallel study to compare the change in HbA1c with AVANDAMET® (8.0mg / 2.0g) plus insulin to placebo plus insulin, in subjects with type 2 diabetes starting insulin therapy Study Listed on ClinicalStudyDataRequest.com
712753/011 Completed A study to assess the effect of food and time of dosing on the pharmacokinetics of Avandamet™ (rosiglitazone maleate 8 mg/metformin HCl 1000 mg administered as 2 × 4/500) Glucophage XR 1000 mg (given as metformin HCl 2 × 500 mg) and Avandia™ (rosiglitazone maleate 8 mg) in healthy adult subjects. Study Listed on ClinicalStudyDataRequest.com
712753/012 Completed A study to estimate the pharmacokinetics of six extended release formulations of AVANDAMET (rosiglitazone maleate 4mg / metformin HCl 1000mg), compared to the commercial formulation of AVANDAMET (rosiglitazone maleate 2mg / metformin HCl 500mg, q12h), and concomitant dosing of Glucophage XR (metformin HCl 2 × 500mg) with AVANDIA (rosiglitazone maleate 4mg) Study Listed on ClinicalStudyDataRequest.com
712753/014 Completed A study to assess the steady state pharmacokinetics of repeat oral doses of AVANDAMET XR (combination formulation of rosiglitazone 8mg/metformin 1000mg) and AVANDAMET IR (rosiglitazone 4mg/metformin 500mg) in healthy subjects Study Listed on ClinicalStudyDataRequest.com
719125/002 Completed A multicenter Phase I open-label dose-escalation vaccine trial of dHER2 protein with AS15 adjuvant in HER2-overexpressing patients with high-risk breast cancer
743830/002 Completed An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 150 mg Ibandronate to 3 x 50 mg Tablets of Ibandronate Study Listed on ClinicalStudyDataRequest.com
743830/003 Completed An Open-label, Randomized, Replicate, Four-Period Crossover Study in Healthy Post-Menopausal Women to Assess the Bioequivalence of a Single Unit Dose Tablet of 100mg Ibandronate to 2 x 50 mg Tablets of Ibandronate Study Listed on ClinicalStudyDataRequest.com
75 Completed Six-week, multicenter, double-blind, randomized, parallel comparison of the efficacy and safety of bupropion versus placebo in children with attention deficit disorder – Extensive searching has revealed that no clinical study report is available for this study.
759346/001 Completed A phase II, open, randomized, controlled study to evaluate the immunogenicity of investigational vaccinationregimens administered as a three dose primary vaccination course at 6, 10 and 14 weeks of age. Study Listed on ClinicalStudyDataRequest.com
759346/002 Completed Assess immune persistence & memory by giving plain PRP,PSA & PSC (10 mths age), & immunogenicity & safety of a Tritanrix™-HBV/Hib-MenAC/ Tritanrix™-HBV/Hib2.5 booster (15-18 mths age) in previously primed subjects Study Listed on ClinicalStudyDataRequest.com
759346/007 Completed Demonstrate non-inferiority of GSK Biologicals’ Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ with respect to anti-HBs immune response, when given to healthy infants at 6,10 & 14 weeks age, after a birth dose of hepatitis B vaccine Study Listed on ClinicalStudyDataRequest.com
759346/009 Completed Study to evaluate immunogenicity, reactogenicity and safety of investigational vaccination regimen as compared to GSK Biological’s Hiberix vaccine, extemporaneously mixed with GSK Biological’s Tritanrix-HepB, when administered intramuscularly in infants at 6, 10 and 14 weeks of age Study Listed on ClinicalStudyDataRequest.com
759348/001 Completed A randomised, controlled phase II study to evaluate the safety and immunogenicity of 7 different formulations of GSK Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunisation schedule before 6 months of age, followed by a fourth dose during the second year of life Study Listed on ClinicalStudyDataRequest.com
759348/002 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of 7 different formulations of an investigational vaccination regimen, when administered as a 3-dose primary immunization schedule before 6 months of age, followed by a fourth dose during the second year of life
759348/003 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of four different formulations of GlaxoSmithKline (GSK) Biologicals’ investigational vaccination regimen, when administered as a 3-dose primary immunization schedule beginning before 6 months of age. Study Listed on ClinicalStudyDataRequest.com
759348/007 Completed A randomized, controlled, phase II study to evaluate the safety and immunogenicity of five formulations of GlaxoSmithKline Biologicals’ investigational vaccination regimen, when administered intramuscularly as a 3-dose primary immunization schedule (2-3-4 month schedule) before 6 months of age.
763310/001 Completed A phase I/II trial of an investigational vaccination regimen in infants.
763674/001 Completed A phase II, open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age. Study Listed on ClinicalStudyDataRequest.com
763674/002 Completed A phase II open, randomized, controlled study to evaluate an investigational vaccination regimen administered as athree dose primary vaccination course at 2, 3 and 4 months of age. Study Listed on ClinicalStudyDataRequest.com
773812/007 Completed A Parallel Study to Investigate Dopaminergic D2 and Serotoninergic 5HT2A Receptor Occupancy at Stable Plasma Concentrations of SB-773812 after Repeated Doses in Schizophrenic Patients. Relationship with Pharmacokinetics and Efficacy Readouts.
776423/001 Completed A phase III, observer-blinded randomised, multi-centre clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GSK Biologicals' candidate Tdap vaccine as compared to a US-licensed Td vaccine when given as a booster dose to healthy adolescents (10-18 years of age) Study Listed on ClinicalStudyDataRequest.com
782528/902 Completed A six way crossover study to evaluate the impact of dosing of 10 mg vardenafil and 50 mg sildenafil concomitantly with 400 mg gatifloxacin on cardiac conduction for 16 h post-dose in healthy male subjects aged 18 to 64.
792014/001 Completed A phase II, open (partially double-blind), randomised, controlled, multicentre, primary vaccination study to evaluate the immunogenicity (including immune memory), reactogenicity and safety of three different formulations of the GSK Biologicals’ combined Haemophilus influenzae type b-meningococcal serogroups CY conjugate vaccine given concomitantly with Infanrix® penta and Prevenar®, versus ActHIB® and Meningitec® given concomitantly with Infanrix® penta and versus ActHIB® given concomitantly with Infanrix® penta and Prevenar® in infants according to a 2-4-6 month schedule. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.